{
    "clinical_study": {
        "@rank": "114302", 
        "arm_group": [
            {
                "arm_group_label": "Cohort I (no therapy)", 
                "arm_group_type": "No Intervention", 
                "description": "Patients receive no treatment after completion of standard sipuleucel-T therapy."
            }, 
            {
                "arm_group_label": "Cohort II (glycosylated recombinant human interleukin-7)", 
                "arm_group_type": "Experimental", 
                "description": "Patients receive glycosylated recombinant human interleukin-7 SC on days 0, 7, and 14 beginning 3-7 days after completion of standard sipuleucel-T therapy. Treatment continues in the absence of disease progression or unacceptable toxicity."
            }
        ], 
        "brief_summary": {
            "textblock": "This randomized phase II trial studies how well biological therapy with or without vaccine\n      therapy works in treating patients with metastatic hormone-resistant prostate cancer.\n      Biological therapies may stimulate the immune system in different ways and stop tumor cells\n      from growing. Vaccines may help the body build an effective immune response to kill tumor\n      cells. It is not yet known whether biological therapy is more effective with or without\n      vaccine therapy in treating prostate cancer."
        }, 
        "brief_title": "Biological Therapy With or Without Vaccine Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer", 
        "condition": [
            "Hormone-resistant Prostate Cancer", 
            "Recurrent Prostate Cancer", 
            "Stage IV Prostate Cancer"
        ], 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. To determine whether CYT107 (glycosylated recombinant human interleukin-7) administration\n      increases the vaccine-induced antigen-specific T-cell immune response to the sipuleucel-T\n      fusion protein vaccine construct prostatic acid phosphatase-sargramostim (PAP-GM-CSF)\n      (PA2024).\n\n      SECONDARY OBJECTIVES:\n\n      I. To determine whether CYT107 administration increases the vaccine-induced antigen-specific\n      T-cell immune response to PAP.\n\n      II. To assess the character of the T-cell immune response to PAP and PA2024.\n\n      III. To determine whether CYT107 administration increases the vaccine-induced\n      antigen-specific antibody immune responses to PAP and PA2024.\n\n      IV. To quantify the effects of CYT107 on T-cell repertoire diversity.\n\n      V. To assess the effects of CYT107 on the immune competence of patients with advanced\n      prostate cancer.\n\n      VI. To assess the clinical efficacy and tolerability of sipuleucel-T plus CYT107 compared\n      with sipuleucel-T alone.\n\n      OUTLINE: Patients are randomized to 1 of 2 treatment cohorts.\n\n      COHORT I: Patients receive no treatment after completion of standard sipuleucel-T therapy.\n\n      COHORT II: Patients receive glycosylated recombinant human interleukin-7 subcutaneously (SC)\n      on days 0, 7, and 14 beginning 3-7 days after completion of standard sipuleucel-T therapy.\n      Treatment continues in the absence of disease progression or unacceptable toxicity.\n\n      After completion of study treatment, patients are followed up for 52 weeks."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer\n             (mCRPC)\n\n          -  Patients must have successfully completed therapy with sipuleucel-T within 3-7 days\n             of planned CYT107 study drug treatment\n\n          -  Assessable disease with a positive bone scan and/or measurable disease on computed\n             tomography (CT) scan and/or magnetic resonance imaging (MRI) of the abdomen and\n             pelvis\n\n          -  Prior orchiectomy or must be on ongoing luteinizing hormone-releasing hormone (LHRH)\n             agonist or antagonist (e.g., degarelix) therapy\n\n          -  No ongoing anti-androgen therapy; patients must be off anti-androgen therapy for at\n             least 30 days\n\n          -  Patients receiving any other hormonal therapy, including any dose of megestrol\n             acetate (Megace), Proscar (finasteride), any herbal product known to decrease\n             prostate specific antigen (PSA) levels (e.g. Saw Palmetto, PC-SPES), or any systemic\n             corticosteroid, must discontinue the agent for at least 30 days prior to study\n             treatment\n\n          -  Absolute neutrophil count (ANC) >= 1500/\u00b5L\n\n          -  Bilirubin < 1.5 x upper limit of normal (ULN)\n\n          -  Hemoglobin >= 10 g/dL\n\n          -  PSA >= 2 ng/mL\n\n          -  Platelets >= 100,000/mcL\n\n          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN\n\n          -  Creatinine clearance >= 60 mL/min by the Cockcroft-Gault equation\n\n          -  Testosterone =< 50 ng/dL (documented at any time while on LHRH agonist or antagonists\n             odds ratios [ors]/orchiopexy [p] orchiectomy)\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 or a Karnofsky\n             performance status of >= 80%\n\n          -  Life expectancy of at least 6 months\n\n          -  Prior local radiation therapy must be completed at least 30 days prior to enrollment\n             and the patient must have recovered from all toxicity\n\n          -  Prior \"systemic\" radiopharmaceuticals (strontium, samarium) must be completed >= 8\n             weeks prior to enrollment\n\n          -  Patients must agree to use adequate contraception (barrier method for males) for the\n             duration of study participation, and for four months after discontinuing therapy,\n             because of the unknown potential risk to a gamete and/or developing embryo from this\n             investigational therapy\n\n          -  Ability to understand and the willingness to sign a written informed consent document\n\n        Exclusion Criteria:\n\n          -  Prior chemotherapy for prostate cancer, with the exception of neoadjuvant\n             chemotherapy, because of the potential effect of chemotherapy on the immune system\n\n          -  Prior investigational immunotherapy\n\n          -  Prostate cancer pain requiring regularly scheduled narcotics\n\n          -  Pathologic long-bone fractures, imminent pathologic long-bone fracture (cortical\n             erosion on radiography > 50%) or spinal cord compression\n\n          -  Current treatment with systemic steroid therapy (inhaled/topical steroids are\n             acceptable); systemic corticosteroids must be discontinued for at least 30 days prior\n             to first CYT107 injection\n\n          -  Known central nervous system metastases\n\n          -  No documented cirrhosis or documented acute hepatitis; Note: a positive hepatitis B\n             serology indicative of previous immunization (i.e., hepatitis B surface antibody\n             [HBsAb] positive and hepatitis B core antibody [HBcAb] negative), or a fully resolved\n             acute hepatitis B (HBV) infection is not an exclusion criterion\n\n          -  No history of severe asthma, as defined by prior or current use of systemic\n             corticosteroids for disease control, with the exception of physiological replacement\n             doses of cortisone acetate or equivalent, as defined by a dose of 10 mg or less\n\n          -  Medical or psychiatric illness that would, in the opinion of the investigator,\n             preclude participation in the study or the ability of patients to provide informed\n             consent for themselves\n\n          -  Cardiovascular disease that meets one of the following: congestive heart failure (New\n             York Heart Association class III or IV), active angina pectoris, or recent myocardial\n             infarction (within the last 6 months)\n\n          -  Concurrent or prior malignancy except for the following:\n\n               -  Adequately treated basal or squamous cell skin cancer\n\n               -  Adequately treated stage I or II cancer from which the patient is currently in\n                  complete remission\n\n               -  Any other cancer from which the patient has been disease-free for 5 years\n\n          -  Known human immunodeficiency virus (HIV) or other history of immunodeficiency\n             disorder; HIV-positive patients on combination antiretroviral therapy are ineligible\n             because of the potential for pharmacokinetic interaction with CYT107; other trials\n             are examining the effect of CYT107 in patients with HIV infection\n\n          -  Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for\n             treatment of either a psychiatric or medical (e.g. infectious) illness\n\n          -  Any underlying medical or psychiatric condition, which in the opinion of the\n             investigator will make the administration of CYT107 hazardous or obscure the\n             interpretation of adverse events (AEs), such as a condition associated with frequent\n             diarrhea\n\n          -  Prior treatment with anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) or experimental\n             check point inhibitor such as anti-programmed-death (PD)1\n\n          -  History of allergic reactions attributed to compounds of similar chemical or biologic\n             composition to CYT107\n\n          -  Patients who have received prior immunosuppressive therapy within 30 days prior to\n             enrollment\n\n          -  Active (as defined by requiring immunosuppressive therapy) or history of clinically\n             significant autoimmune disease (as defined by previously requiring immunosuppressive\n             therapy)\n\n          -  Patients who have received hepatotoxic drugs less than 7 days prior to enrollment\n\n          -  Patients who have received prior biologic agents less than 30 days prior to\n             enrollment\n\n          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active\n             infection, congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or\n             psychiatric illness/social situations that would limit compliance with study\n             requirements\n\n          -  Patients who have a history of any hematopoietic malignancy\n\n          -  History of pulmonary disease such as emphysema or chronic obstructive pulmonary\n             disease (COPD), (forced expiratory volume [FEV] > 60% of predicted for height and age\n             required in patients with prolonged smoking history or symptoms or respiratory\n             dysfunction)"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01881867", 
            "org_study_id": "CITN12-03", 
            "secondary_id": [
                "NCI-2013-00998", 
                "U01CA154967"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Cohort II (glycosylated recombinant human interleukin-7)", 
                "description": "Given SC", 
                "intervention_name": "glycosylated recombinant human interleukin-7", 
                "intervention_type": "Biological", 
                "other_name": [
                    "CYT107", 
                    "glycosylated rhIL-7"
                ]
            }, 
            {
                "arm_group_label": "Cohort II (glycosylated recombinant human interleukin-7)", 
                "description": "Correlative studies", 
                "intervention_name": "laboratory biomarker analysis", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 28, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Lawrence Fong", 
                    "phone": "415-514-3160"
                }, 
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94143"
                    }, 
                    "name": "University of California"
                }, 
                "investigator": {
                    "last_name": "Lawrence Fong", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Omer Kucuk", 
                    "phone": "404-778-1900"
                }, 
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30322"
                    }, 
                    "name": "Winship Cancer Institute of Emory University"
                }, 
                "investigator": {
                    "last_name": "Omer Kucuk", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "John Seigne", 
                    "phone": "603-650-6052"
                }, 
                "facility": {
                    "address": {
                        "city": "Lebanon", 
                        "country": "United States", 
                        "state": "New Hampshire", 
                        "zip": "03756"
                    }, 
                    "name": "Dartmouth-Hitchcock Medical Center"
                }, 
                "investigator": {
                    "last_name": "John Seigne", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Anna Ferrari", 
                    "phone": "212-731-5389"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10016"
                    }, 
                    "name": "NYU Langone Medical Center"
                }, 
                "investigator": {
                    "last_name": "Anna Ferrari", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Evan Yu", 
                    "phone": "206-288-1152"
                }, 
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98109"
                    }, 
                    "name": "Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium"
                }, 
                "investigator": {
                    "last_name": "Evan Yu", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 2 Study of Recombinant Glycosylated Human Interleukin-7 (CYT107) After Completion of Standard FDA Approved Therapy With Sipuleucel-T (Provenge\u00ae) for Patients With Asymptomatic or Minimally Symptomatic Metastatic Castration-resistant Prostate Cancer (mCRPC)", 
        "overall_official": {
            "affiliation": "Cancer Immunotherapy Trials Network", 
            "last_name": "Lawrence Fong", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Institutional Review Board", 
                "United States: Food and Drug Administration"
            ]
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The Mann-Whitney-Wilcoxon (MWW) test will be used as part of the statistical analysis; the power is roughly equivalent to that based on the t-test.", 
            "measure": "Quantification of T-cell responses to prostatic acid phosphatase-sargramostim fusion protein", 
            "safety_issue": "No", 
            "time_frame": "Day 70 (week 11)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01881867"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Increase in antigen-specific T-cell immune responses to prostatic acid phosphatase", 
                "safety_issue": "No", 
                "time_frame": "Day 70 (week 11)"
            }, 
            {
                "description": "The absolute change in each parameter as well as variance in change over time for each patient (mean, median, and standard error [SE]/standard deviation [SD]) will be evaluated.", 
                "measure": "Number and percentage of peripheral blood mononuclear cell (PBMC) subsets and T lymphocyte subsets", 
                "safety_issue": "No", 
                "time_frame": "Up to week 53"
            }, 
            {
                "measure": "Increase in the vaccine-induced antigen-specific antibody immune responses to prostatic acid phosphatase and prostatic acid phosphatase-sargramostim fusion protein", 
                "safety_issue": "No", 
                "time_frame": "Up to week 53"
            }, 
            {
                "measure": "Quantification of glycosylated recombinant human interleukin-7 on T-cell diversity", 
                "safety_issue": "No", 
                "time_frame": "Week 5"
            }, 
            {
                "measure": "Bystander antigen specific immune responses and thymic function", 
                "safety_issue": "No", 
                "time_frame": "Up to week 53"
            }, 
            {
                "measure": "Incidence of adverse events graded and reported using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0", 
                "safety_issue": "Yes", 
                "time_frame": "Up to week 53"
            }, 
            {
                "description": "The 95% confidence intervals should be provided.", 
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "Up to week 53"
            }, 
            {
                "description": "The 95% confidence intervals should be provided.", 
                "measure": "PSA kinetics evaluated according to the recommendations from PSA Working Group (PSAWG)", 
                "safety_issue": "No", 
                "time_frame": "Up to week 53"
            }, 
            {
                "description": "The 95% confidence intervals should be provided.", 
                "measure": "Progression free survival assessed by Response Evaluation Criteria in Solid Tumors (RECIST) criteria for measurable disease by bone scans and radiographic criteria for non-measurable bony metastasis", 
                "safety_issue": "No", 
                "time_frame": "Time from start of treatment to time of radiographic progression or death, assessed up to week 53"
            }
        ], 
        "source": "Fred Hutchinson Cancer Research Center", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Fred Hutchinson Cancer Research Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}